Boston Trust Walden’s Novo Nordisk NVO Stock Holding History

Boston Trust Walden’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$580K	Buy	12,091 +55	+0.5%	+$2.36K	﹤0.01%	327
2026 Q1	$442K	Hold	12,036	–	–	﹤0.01%	340
2025 Q4	$612K	Hold	12,036	–	–	﹤0.01%	313
2025 Q3	$668K	Hold	12,036	–	–	﹤0.01%	308
2025 Q2	$831K	Buy	12,036 +6,670	+124%	+$454K	0.01%	287
2025 Q1	$373K	Hold	5,366	–	–	﹤0.01%	333
2024 Q4	$462K	Hold	5,366	–	–	﹤0.01%	320
2024 Q3	$639K	Hold	5,366	–	–	﹤0.01%	308
2024 Q2	$766K	Hold	5,366	–	–	0.01%	292
2024 Q1	$689K	Sell	5,366 -13,980	-72%	-$1.66M	﹤0.01%	302
2023 Q4	$2M	Hold	19,346	–	–	0.02%	246
2023 Q3	$1.76M	Hold	19,346	–	–	0.01%	251
2023 Q2	$1.57M	Buy	19,346 +1,000	+5%	+$81.7K	0.01%	257
2023 Q1	$1.46M	Sell	18,346 -400	-2%	-$28.4K	0.01%	255
2022 Q4	$1.27M	Sell	18,746 -184	-1%	-$10.8K	0.01%	267
2022 Q3	$943K	Hold	18,930	–	–	0.01%	275
2022 Q2	$1.05M	Sell	18,930 -100	-0.5%	-$5.55K	0.01%	272
2022 Q1	$1.06M	Sell	19,030 -100	-0.5%	-$5.13K	0.01%	277
2021 Q4	$1.07M	Sell	19,130 -100	-0.5%	-$5.42K	0.01%	282
2021 Q3	$923K	Buy	19,230 +1,100	+6%	+$53.2K	0.01%	287
2021 Q2	$759K	Buy	18,130 +250	+1%	+$9.69K	0.01%	299
2021 Q1	$603K	Buy	17,880 +550	+3%	+$19.6K	0.01%	310
2020 Q4	$605K	Hold	17,330	–	–	0.01%	307
2020 Q3	$602K	Hold	17,330	–	–	0.01%	304
2020 Q2	$567K	Hold	17,330	–	–	0.01%	305
2020 Q1	$522K	Sell	17,330 -190	-1%	-$5.66K	0.01%	302
2019 Q4	$507K	Buy	17,520 +2,190	+14%	+$60.6K	0.01%	322
2019 Q3	$396K	Hold	15,330	–	–	0.01%	336
2019 Q2	$391K	Hold	15,330	–	–	0.01%	339
2019 Q1	$401K	Sell	15,330 -70	-0.5%	-$1.72K	0.01%	343
2018 Q4	$355K	Sell	15,400 -3,350	-18%	-$74.4K	0.01%	341
2018 Q3	$442K	Hold	18,750	–	–	0.01%	339
2018 Q2	$432K	Sell	18,750 -900	-5%	-$21.4K	0.01%	339
2018 Q1	$484K	Buy	19,650 +3,200	+19%	+$84K	0.01%	335
2017 Q4	$441K	Buy	+16,450	New	+$418K	0.01%	343
2015 Q3	–	Sell	-9,700	Closed	-$266K	–	355
2015 Q2	$266K	Buy	9,700 +2,200	+29%	+$61.8K	﹤0.01%	338
2015 Q1	$200K	Buy	+7,500	New	+$173K	﹤0.01%	339

Other funds holding NVO

SRIM

Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

AIIMS

Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

GIM

Generate Investment Management Auckland, New Zealand $2.43B AUM 37.24% 1-Year Est. Return

CFB

Cullen/Frost Bankers San Antonio, Texas $10.1B AUM 29.18% 1-Year Est. Return

Boston Trust Walden's NVO Position: Q2 2026 in Review

Boston Trust Walden increased its Novo Nordisk (NVO) stake by 0.46% in Q2 2026, buying an estimated $2.36K and bringing the position to 12,091 shares worth $580K. The position accounts for ﹤0.01% of the portfolio, ranked #327.

Boston Trust Walden first reported a position in NVO in Q1 2015 and has held it in 37 quarters since. The position peaked at $2M in Q4 2023. 543 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Boston Trust Walden held 12,091 shares of Novo Nordisk worth $580K as of Q2 2026.
Boston Trust Walden bought 55 Novo Nordisk shares in Q2 2026, an estimated $2.36K.
Novo Nordisk made up ﹤0.01% of Boston Trust Walden's portfolio in Q2 2026, its #327 holding.
Boston Trust Walden first reported a position in Novo Nordisk in Q1 2015 and has held it in 37 quarters since.
Boston Trust Walden's Novo Nordisk position peaked at $2M in Q4 2023.
543 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Boston Trust Walden's 13F filing for Q2 2026, filed 24 Jul 2026.